Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional IL-2 for Resectable TNBC
NCT05821686Phase 2Not yet recruiting
- Sponsor
- Nova Scotia Health
- Start
- Jan 2026
- Primary completion
- Apr 2028
- Modality
- Cytokines & Interferons
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in triple-negative breast cancer (TNBC), sponsored by Nova Scotia Health. Primary endpoint: Pathologic response as defined by the residual cancer burden (RCB) index. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
aldesleukin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05821686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05821686.